These observations were further supported by the ARETHUSA trial, which treated patients with colorectal cancer with “TMZ priming” followed by pembrolizumab and revealed acquired MSH6 variants, a genomic signature for TMZ, and increased tumor mutational burden after the “TMZ priming” (22). The gene discussed is MSH6; the disease is neoplasm.